It is important to remark, however, that there is extensive evidence that points to a high rate of multiple resistances, and therefore the combined use of EGFR Tyrosine Kinase Inhibitors (TKIs) along with GLI-1 inhibitors is being recommended for NSCLC patients who may have an epithelial-mesenchymal transition (EMT) as a result of therapy resistance. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.